Clinical Trial

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Monotherapy and Combination Therapy in patients with advanced HER2-Expressing Solid Tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-06; most recent amendment 2025-08-01.
Status change: Not Yet Recruiting → Recruiting 2025-08-01
Trial Details
NCT Number NCT07022002
Lead Sponsor Shenyang Sunshine Pharmaceutical Co., LTD.
Conditions Locally Advanced, Recurrent or Metastatic Malignancies
Enrollment 340 participants
Start Date 2025-07-30
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-03